MECHANISMS OF STEROID ACTION AND RESISTANCE IN INFLAMMATION

Corticosteroid-insensitive asthma: molecular mechanisms

I M Adcock and S J Lane1
Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
1Department of Respiratory Medicine, Adelaide and Meath Hospital, Tallaght, Dublin 24, Eire
(Requests for offprints should be addressed to I M Adcock; Email: ian.adcock@imperial.ac.uk)

Abstract

Corticosteroids are the most potent anti-inflammatory agents used to treat chronic inflammatory diseases such as bronchial asthma. However, there are a small number (<5%) of asthmatic patients who do not respond well, or at all, to corticosteroid therapy – the corticosteroid-resistant and corticosteroid-dependent patients. Although this phenomenon is relatively uncommon, it poses a difficult therapeutic problem because few alternative therapies are available and these patients account for >50% of the health care costs of asthma. If the mechanisms for corticosteroid insensitivity are understood they may, in turn, provide insight into the key mechanism of corticosteroid action and allow a rational way to treat these individuals whose disease tends to be severe. Corticosteroid insensitivity is not limited to asthma and is a feature of other inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Thus, elucidation of the cause for the relative lack of corticosteroid response in this subgroup of asthmatic individuals may have important implications for other diseases.


The molecular basis of inflammation in bronchial asthma

Inflammation is a central feature of many chronic lung diseases including bronchial asthma. The specific characteristics of the inflammatory response and the site of inflammation differ between these diseases, but all involve the recruitment and activation of inflammatory cells and changes in the structural cells of the lung. These diseases are characterised by an increased expression of many mediators involved in the inflammatory cascade, including cytokines, chemokines, growth factors, enzymes, receptors and adhesion molecules. Increased inflammatory gene transcription is regulated by pro-inflammatory transcription factors, such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1). For example, NF-κB (Hart et al. 1998) and AP-1 (Demoly et al. 1992) are markedly activated in the epithelial cells of asthmatic patients and these transcription factors regulate many of the inflammatory genes that are abnormally expressed in asthma (Adcock & Caramori 2001).

Alterations in the structure of chromatin are critical to the regulation of gene expression (Urnov & Wolffe 2001). This chromatin structure is composed of nucleosomes which are particles consisting of ~146 bp DNA associated with an octomer of two molecules each of core histone proteins (H2A, H2B, H3 and H4). In the resting cell, DNA is tightly compacted around these basic core histones, excluding the binding of the enzyme RNA polymerase II, which activates the formation of mRNA. This conformation of the chromatin structure is described as closed and is associated with suppression of gene expression. Acetylation of lysine residues on histones induces a relaxed DNA structure allowing gene transcription to occur. Transcriptional co-activators such as cAMP response element binding protein (CREB)–binding protein (CBP) have intrinsic histone acetyltransferase (HAT) activity, which is further activated by the binding of transcription factors. Changes in the phosphorylation status of HATs also affect their activity. Increased gene transcription is therefore associated with an increase in histone acetylation, whereas hypo-acetylation is correlated with reduced transcription or gene silencing (Urnov & Wolffe 2001).

NF-κB and AP-1

NF-κB is ubiquitously expressed and is able not only to control the induction of inflammatory genes in its own
right but it can enhance the activity of other cell- and signal- specific transcription factors (Barnes & Karin 1997). In addition, it is a major target for corticosteroids (Barnes & Karin 1997). NF-κB is activated by all the stimuli thought to be important in asthma, including cytokines, such as tumour necrosis factor-α (TNFα) and interleukin (IL)-1β, viruses and immune challenges (Barnes & Karin 1997, Baldwin 2001). Activation of cell surface receptors leads to phosphorylation of receptor-associated kinases. These kinases, in turn, phosphorylate specific intracellular kinases (inhibitor of NF-κB kinase; IκK). Phosphorylation of IκKs results in phosphorylation of the NF-κB cytoplasmic inhibitor (I-κBα), which targets I-κBα for proteasomal degradation. This releases NF-κB from its inactive state, enabling nuclear translocation and binding to specific DNA response elements within the regulatory regions of responsive genes (Ghosh & Karin 2002).

AP-1 is a transcription factor complex that is formed by dimerisation of members of the Fos (c-Fos, Fra1 and Fra2) and Jun (c-Jun, Jun B and Jun D) proto-oncogene families and is defined by binding to the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA)-response element (TRE) (Chang & Karin 2001, Shaulian & Karin 2002). In the resting cell, AP-1 is composed of dimers of the Jun family and has weak DNA binding and gene transactivating activities. When the cell is activated, the components of AP-1 change rapidly to Fos:Jun heterodimers of which c-Fos:c-Jun is the most abundant and much more active than the resting homodimer. Inducible AP-1 is formed after activation of specific mitogen-activated protein kinases (MAPKs) of which Jun N-terminal kinase (JNK) is a central component (Chang & Karin 2001). JNK increases AP-1’s DNA binding and gene transactivating activity by increasing the production of c-Fos and by increasing the affinity of c-Jun for c-Fos. JNK also phosphorylates Ets-like kinase (Elk-1) which enhances c-Fos transcription (Chang & Karin 2001) by binding to the serum response element in its promoter. c-Jun transcriptional activation is mediated by a TRE that is bound by the transcriptional activator activating transcription factor 2 (ATF-2), either as a homodimer or as a heterodimer with c-Jun. In this way, c-Jun may autoregulate expression of its own gene. In addition, ATF-2 is phosphorylated by JNK (Chang & Karin 2001, Shaulian & Karin 2002) leading to increased c-Jun expression.

**Glucocorticoid receptors**

Corticosteroids exert their effects by binding to a cytoplasmic receptor (glucocorticoid receptor; GR) (Adcock & Caramori 2001). GRs are expressed in almost all cell types and are modular in structure. Thus, GR has several functional domains including a ligand-binding domain (LBD), a DNA-binding domain and two domains that are involved in transactivation of genes once binding to DNA has occurred via association with other proteins (activation function; AF-1 and AF-2). The second activation domain (AF-2) lies within the LBD. The inactive GR is bound to a protein complex that includes two subunits of the heat shock protein hsp90, which thus act as molecular chaperones preventing the nuclear localisation of unoccupied GR. Once the ligand binds to GR, hsp90 dissociates, allowing the nuclear localisation of the activated GR–steroid complex and its binding as a dimer to specific DNA sequences (glucocorticoid response elements (GREs); GGTTAACAnntTGTTTCT) and interaction with co-activator complexes (Adcock & Caramori 2001).

**Glucocorticoid-induced gene transcription**

The number of genes per cell directly regulated by corticosteroids is estimated to be between 10 and 100, but many genes are indirectly regulated through an interaction with other transcription factors and co-activators. Corticosteroids may suppress inflammation by increasing the synthesis of anti-inflammatory proteins, such as annexin-1, IL-10, MAPK phosphatase-1 (MKP-1) and the inhibitor of NF-κB, I-κBα (Table 1). Glucocorticoid side-effects are manifold and their regulation, at the molecular level, involves both DNA-binding and non-DNA-binding events. It is likely that some side-effects, such as osteoporosis, glaucoma, growth retardation in children, wound healing and metabolic effects are mediated, at least in part, by DNA binding (Schacke et al. 2002a). GRs, as with other transcription factors, increase gene transcription through an action on chromatin remodelling and recruitment of RNA polymerase II to the site of local DNA unwinding (Karin 1998, Ito et al. 2000).

**Switching off inflammatory genes**

**Cross-talk between GR and other transcription factors**

The major anti-inflammatory effects of corticosteroids are thought to be due to repression of inflammatory and immune genes. The inhibitory effect of corticosteroids is due largely to protein–protein complex interactions between activated GR and transcription factors, such as NF-κB and AP-1, which mediate the expression of these inflammatory genes (Karin 1998) (Fig. 1). The interplay between pro-inflammatory transcription factors and GR may reflect differing effects on histone acetylation/deacetylation (Ito et al. 2000).

The importance of cross-talk in GR actions is indicated by the construction of a GR dimerisation-deficient mutant mouse in which GR is unable to dimerise and therefore bind to DNA, thus separating the transactivation and transrepression activities of glucocorticoids (Reichardt et al. 1998). These animals, in contrast to GR knock-out animals, survive to adulthood. In these animals,
Dexamethasone was able to inhibit AP-1- and NF-κB-driven gene transcription but the ability to facilitate GRE-mediated effects such as cortisol suppression and thymocyte apoptosis was markedly attenuated. This also suggests that the development of glucocorticoids with a greater therapeutic window is possible.

In addition, corticosteroids may also play a role in repressing the action of MAPKs such as the extracellular regulated kinase (ERK) and JNK (Rider et al. 1996, Caelles et al. 1997, Swantek et al. 1997, Hirasawa et al. 1998). Thus, Caelles and colleagues have demonstrated that corticosteroids inhibit the phosphorylation and activation of JNK, resulting in a failure to phosphorylate c-Jun and Elk-1, reduced c-fos transcription and a marked reduction in AP-1 activity. More recently it has been shown that dexamethasone can rapidly induce the dual specificity MAPK inhibitor MKP-1 and thereby attenuate p38 MAPK activation (Kassel et al. 2001, Lasa et al. 2001, 2002). Rogatsky et al. (1998) have, in turn, shown reciprocal inhibition of rat GR reporter gene activity by JNKs by a direct phosphorylation of serine 246 whereas ERK can inhibit GR action by an indirect effect, possibly through phosphorylation of a co-factor.

**Corticosteroid resistance**

Although corticosteroids are highly effective in the control of asthma and other chronic inflammatory or immune diseases, a small proportion of patients with asthma fail to respond even to high doses of oral corticosteroids (Leung & Bloom 2003). Resistance to the therapeutic effects of corticosteroids is also recognised in other inflammatory and immune diseases (Lamberts et al. 1996), including rheumatoid arthritis (Lane & Lee 1996) and inflammatory bowel disease (Hearing et al. 1999). Corticosteroid-resistant (CR) patients, although uncommon, present considerable management problems. It is likely that there is a spectrum of steroid responsiveness, with the rare resistance at one end, but a relative resistance is seen in patients who require high doses of inhaled and oral corticosteroids (corticosteroid-dependent asthma; CD) (Leung & Bloom 2003).

CR asthma has been defined as a failure of the forced expired volume in 1s to improve from a baseline value of ≥75% predicted by ≥15% after 14 days of treatment with 40 mg prednisolone orally, despite demonstrating >15% reversibility to an inhaled β2 agonist (Barnes et al. 1995). In addition to reduced changes in clinical symptoms following corticosteroid therapy, studies have shown that there is reduced suppression of IL-4 and IL-5 mRNA in bronchoalveolar lavage cells obtained from CR patients after 1 week of treatment with prednisolone, when compared with those of corticosteroid-sensitive (CS) asthmatic subjects (Leung et al. 1995). Bronchoalveolar lavage of a group of CR subjects revealed an increased number of cells expressing IL-2, IL-4 and IL-13 mRNA compared with CS asthmatics (Leung et al. 1995). This suggested

---

**Table 1** Glucocorticoid-sensitive genes

<table>
<thead>
<tr>
<th>Increased transcription</th>
<th>Decreased transcription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipoprotein-1/annexin-1 (phospholipase A₂ inhibitor)</td>
<td>Cytokines</td>
</tr>
<tr>
<td>β₂-adrenoceptor</td>
<td>(IL-1, 2, 3, 4, 5, 6, 9, 11, 12, 13, 16, 17, 18, TNFα, GM-CSF, SCF)</td>
</tr>
<tr>
<td>Secretory leukocyte inhibitory protein (SLPI)</td>
<td>Chemokines</td>
</tr>
<tr>
<td>Clara cell protein (CC10, phospholipase A₂ inhibitor)</td>
<td>(IL-8, RANTES, MIP-1α, MCP-1, MCP-3, MCP-4, eotaxin)</td>
</tr>
<tr>
<td>IL-1 receptor antagonist</td>
<td>Inducible nitric oxide synthase (iNOS)</td>
</tr>
<tr>
<td>IL-1R2 (decoy receptor)</td>
<td>Inducible cyclo-oxygenase (COX-2)</td>
</tr>
<tr>
<td>IκB (inhibitor of NF-κB)</td>
<td>Endothelin-1</td>
</tr>
<tr>
<td>MKP-1 (MAPK phosphatase)</td>
<td>NK₁ receptors, NK₂ receptors</td>
</tr>
<tr>
<td>CD163 (scavenger receptor)</td>
<td>Adhesion molecules (ICAM-1, E-selectin)</td>
</tr>
<tr>
<td></td>
<td>Cytoplasmic phospholipase A₂ (cPLA₂)</td>
</tr>
</tbody>
</table>

CD163, cluster differentiation 163; GM-CSF, granulocyte macrophage-stimulating factor; SCF, stem cell factor; RANTES, Regulated upon activation normal T-cell expressed and secreted; MIP, macrophage inflammatory protein-1α; MCP, monocyte chemoattractant protein; NK, neurokinin; ICAM, intercellular adhesion molecule 1.
that the profile of cytokine expression may underlie the poor responsiveness to glucocorticoids in these patients. Importantly for examining the molecular basis of corticosteroid insensitivity, CR asthma is also associated with impaired in vitro and in vivo responsiveness of peripheral blood mononuclear cells (PBMCs) to the suppressive effects of corticosteroids. Thus, in patients with CR and CD asthma there is a reduction in the inhibitory effect of corticosteroids on cytokine release in PBMCs (Dong et al. 1998, Kam et al. 1993, Leung & Bloom 2003).

Defects in GR sequence and pharmacokinetics
Unlike familial corticosteroid resistance where there is a mutation in the LBD of GR and a subsequent resetting of the basal cortisol level, CR patients have normal cortisol levels and are not Addisonian (Malchoff et al. 1993). Using standard dexamethasone suppression tests, it has been shown that CR asthmatics do not have an altered secretory rate of endogenous cortisol or an altered sensitivity of the hypothalamic–pituitary–adrenal axis (Lane et al. 1996). Using chemical mutational analysis, no mutations in the GR of CR patients were observed (Lane et al. 1994). This was confirmed in a later study which used RT-PCR.

Figure 1 How glucocorticoids switch off inflammatory genes. Inflammatory genes are activated by inflammatory stimuli, such as IL-1β or TNFα, acting through their receptors (CyR), resulting in activation of the transcription factors NF-κB and AP-1. Upon activation, these are able to bind to specific recognition sites within the promoter regions of responsive genes (TF-RE) and stimulate transcription of inflammatory genes such as cytokines and other mediators following recruitment of the basal transcription complex (BTC). GRs, after activation by corticosteroids, translocate to the nucleus and bind to either a negative GR response element (nGRE) in the promoter of inflammatory genes inhibiting gene transcription or, more commonly, interact with and block the ability of AP-1 and NF-κB from enhancing gene expression.
(Adcock et al. 1995b). It is unlikely, therefore, that the defect in CR asthma lies in the structure of the GR.

Defects in ligand binding

We, and others, have previously demonstrated using whole cell binding assays no significant changes in monocyte and T-cell binding affinity ($K_d$) and receptor density of the GR in patients with CR asthma (Corrigan et al. 1991, Lane & Lee 1991). More recently, Sher et al. (1994) have described two patterns of ligand-binding abnormalities in CR asthma termed type 1 and 2. The more common type 1 defect was associated with reduced $K_d$ of GR, normal receptor numbers and was specific to T cells. The less common type 2 defect was associated with reduced GR receptor density with a normal $K_d$ and was seen in the total mononuclear cell population. These differences were detected only in the nucleus and not the cytoplasm, possibly reflecting an effect of a nuclear protein masking the GR ligand-binding site or in an altered conformation of the activated GR. This altered affinity of dexamethasone for GR may reflect either an intrinsic defect in the GR within these patients or may relate to changes in the receptor induced by the increased level of inflammation in more severe asthmatics. The reversal of the reduced binding affinity by incubation with normal media suggests that the latter is a more likely possibility (Irusen et al. 2002, Leung & Bloom 2003). The type 1 defect was reversible with serum deprivation and was mimicked by incubation of cells with high concentrations of IL-2 and IL-4 or by IL-13 alone (Irusen et al. 2002, Leung & Bloom 2003). In contrast, the type 2 defect was irreversible and was not IL-2 and IL-4 dependent (Sher et al. 1994).

Two explanations for the effect of IL-2/IL-4 or IL-13 alone on ligand-binding characteristics have been proposed. Leung & Bloom (2003) have associated these changes with an increased expression of the dominant negative isoform of GR, GRβ, although others have been unable to detect enhanced GRβ expression in PBMCs from these CR patients (Gagliardo et al. 2000, Irusen et al. 2002). In contrast, increased numbers of cells expressing GRβ have been reported in skin biopsies from CR patients (Sousa et al. 2000). We have recently demonstrated that the effects of IL-2/IL-4 or IL-13 on GR-ligand binding and dexamethasone regulation of IL-10 release were blocked by the p38 MAPK inhibitor SB203580. Activation of p38 MAPK by IL-2/IL-4 resulted in serum phosphorylation of GR and reduced dexamethasone repression of lipopolysaccharide (LPS)-stimulated GM-CSF release. The ability of dexamethasone to modulate IL-10 release was also inhibited by IL-2/IL-4 co-treatment and restored by SB203580 (Irusen et al. 2002). These data showed that p38 MAPK inhibitors may have potential in reversing glucocorticoid insensitivity and re-establishing the beneficial effects of glucocorticoids in patients with severe asthma.

It is unclear whether this is a direct or indirect effect of p38 MAPK or whether GR phosphorylation alters ligand binding affinity directly. This may result from either a change in GR conformation due to association of distinct co-factors, or partial blocking of the ligand-binding domain due to association of GR with nuclear transcriptional modulating proteins. Similar results have been seen following NO treatment of GR, whereby nitrosylation of GR at an hsp90 interaction site modified ligand binding (Gagliiana et al. 1999). Serine 226 and the sequences immediately surrounding it are highly conserved, suggesting that its phosphorylation may alter or disrupt the protein–protein interactions regulating GR action.

GR nuclear translocation and GR/GRE binding

In one subgroup of CR and CD patients, nuclear localisation of GR in response to a high concentration (10−8M) of dexamethasone was impaired (Matthews et al. 2000). The mechanism for this effect is unclear but may reflect changes in GR phosphorylation by MAPK and subsequent interaction with importin-α (Rogatsky et al. 1998, Savory et al. 1999, I rusen et al. 2002). This may also explain the earlier results we obtained using (Electrophoretic mobility shift assays (EMSA) which showed that CR patients had a reduced level of GR:GRE binding compared with CS and non-asthmatic individuals following stimulation of PBMCs with dexamethasone (Adcock et al. 1995b). Scatchard analysis of GR:GRE binding showed no change in binding affinity but did show a reduced number of GR available for DNA binding in the CR patients. These results suggest that the ability of GR to bind to GRE is impaired in CR patients because of a reduced number of GR (Adcock et al. 1995b).

In a separate subgroup of CR patients, GR nuclear translocation was normal but dexamethasone could not correctly stimulate histone H4 acetylation (Matthews et al. 2000). This suggests that corticosteroids are not able to activate certain genes that are critical to the anti-inflammatory action of high doses of corticosteroids. The mechanism for this effect is unknown but may reflect the mutual inhibitory effects of excess JNK activation (Rogatsky et al. 1998) in these cells or a failure of GR to recruit specific co-activators.

Cross-talk with other transcription factors

We originally reported an increase in the basal levels of AP-1 DNA binding in the nuclei from CR patients although no differences in the sequences of c-fos and c-jun mRNA were detected. In addition, there was a reduced ability of GR to interact and repress AP-1 activity (Adcock et al. 1995a). It is also possible to see enhanced c-Fos expression in bronchial biopsies of CR patients (Fig. 2).
These results suggested that AP-1 is altered in CR patients and that increased levels of AP-1 may prevent GR function.

In a subsequent study using nuclear run-on, RT-PCR and Western blotting, we demonstrated a two- to fourfold greater increase in the c-fos transcription rate and mRNA and protein expression in PBMCs isolated from CR compared with CS asthmatics and normal subjects (Lane et al. 1998). When cells were stimulated with phorbol 12-myristate 13-acetate (PMA), the time- and concentration-dependent induction of c-Fos was greater in the CR group. Overexpression of c-Fos induced by stimulation of PBMCs derived from CS subjects with PMA for 6 h attenuated the ability of these cells to induce GR-GRE binding after 1 h of dexamethasone treatment. In these experiments, GR-GRE binding was reduced to levels similar to those seen in CR subjects. Incubation of PBMCs derived from CR subjects with dexamethasone and with antisense oligonucleotides directed against c-fos increased GR-GRE binding to levels similar to those seen in CS individuals. These findings suggested that increased c-Fos under basal conditions is the predominant inhibitory activity on GR-DNA binding in CR asthma.

The results of these studies did not determine whether there is a specific abnormality in the activation of c-fos transcription in PBMCs derived from CR subjects or a more generalised activation of the components of AP-1 or their regulatory pathways which activate components of AP-1 through the serum response element (Shaulian & Karin 2002). Using the tuberculin response as a model of mononuclear cell inflammation, Sousa et al. (1999) subsequently showed a marked increase in the expression of activated phosphorylated c-Jun, enhanced expression of JNK, and greater up-regulation of c-Fos expression in the CR compared with the CS group. In this model, prednisolone suppressed memory T-cell, macrophage and

**Figure 2** Enhanced expression of c-Fos in the bronchial airways of steroid (corticosteroid)-resistant (SR) asthmatics compared with steroid-sensitive subjects (SS). Increased intensity of dark brown immunohistological staining of c-Fos within the airway epithelium and infiltrating mononuclear cells in SR compared with SS subjects.
activated eosinophil infiltration into tuberculin-induced skin lesions of CS but not CR individuals. Prednisolone reduced the levels of both phosphorylated c-Jun and phosphorylated JNK in the CS but not the CR group without affecting total c-Jun and JNK expression.

The data to date suggest that increased levels of c-Fos and increased activation of c-Jun in patients with CR asthma account for the increased AP-1 activity seen in vitro and probably relates to increased activation of JNK in these subjects. JNK regulates the expression and activation of both major components of AP-1. Elevated JNK activity could be critical to the mechanisms of CR asthma and failure to inhibit JNK phosphorylation by glucocorticoids may be a major cause for the lack of response to glucocorticoids in CR asthma. In addition, JNK may, in turn, suppress GR function, resulting in a feed-forward loop of increasing inflammation and reduced corticosteroid responsiveness in these patients.

It is unclear whether increased c-fos transcription and JNK activation is a primary or secondary defect caused by excessive production of a unique pattern of cytokines in asthmatic airways. At present there is no evidence for a genetic component leading to enhanced AP-1 activation in CR asthma. The increased numbers of bronchoalveolar lavage cells expressing IL-2 and IL-4 in the CR group may suggest a primary defect of cytokine regulation in these patients. T-helper 2 (TH2) cytokines can enhance AP-1 expression (Wang et al. 1994) which, in turn, can switch on more TH2 cytokines (de Groot et al. 1997), leading to a pro-inflammatory amplification loop. Irrespective of whether enhanced expression of AP-1 is primary or secondary, the net result is an excessive accumulation of this critical transcription factor.

**Therapeutic implications**

Inhaled glucocorticoids are now used as first-line therapy for the treatment of persistent asthma in adults and children in many countries, as they are the most effective...
treatments for asthma currently available (Barnes 1995). However, at high doses systemic absorption of inhaled glucocorticoids may have deleterious effects, so there has been a search for safer glucocorticoids for inhalation and oral administration. This has led to a search for novel glucocorticoids that selectively transrepress without significant transactivation, thus reducing the potential risk of systemic side-effects.

Recently, a novel class of glucocorticoids has been described in which there is potent transrepression with relatively little transactivation. These 'dissociated' glucocorticoids, including RU24858 and RU40066 have anti-inflammatory effects in vitro (Vaysiere et al. 1997), although there is little separation of anti-inflammatory effects and systemic side-effects in vivo (Belvisi et al. 2001). This may reflect in vivo metabolism of the glucocorticoids. Several non-steroidal selective glucocorticoid receptor agonists (SEGRA) have recently been reported that show dissociated properties in human cells (Schacke et al. 2002b). Several of these dissociated glucocorticoids and SEGRA are now in clinical development and show good separation between transrepression and transactivation actions. This suggests that the development of glucocorticoids and SEGRA with a greater margin of safety is possible and may even lead to the development of oral compounds that do not have significant adverse effects. Alternatively, it may be possible to use MAPK inhibitors as steroid-sparing agents reducing the dose of corticosteroid needed to obtain effective therapy.

Conclusions

CR asthma is a syndrome of relative corticosteroid insensitivity, without a clear single pathophysiological cause, rather than a distinct disease with complete resistance to corticosteroids. Several mechanisms have been proposed to account for a failure to respond to corticosteroids (Fig. 3), including a reduced number of GR, altered affinity of the ligand for GR, reduced ability of the GR to bind to DNA or increased activation of transcription factors, such as AP-1, that compete for DNA binding. These events may not be completely exclusive, in that MAPK activation may lead to enhanced inflammation, reduced GR ligand and DNA binding and possibly enhanced GRβ expression. The development of new dissociated corticosteroids may allow high enough doses of corticosteroids to be given to these patients to elicit therapeutic responses bypassing the problem of the deleterious side-effects normally seen in these patients. In addition, MAPK inhibitors may prove to be beneficial as corticosteroid-sparing agents.

References


Sousa AR, Lane SJ, Soh C & Lee TH 1999 \textit{In vivo} resistance to corticosteroids in bronchial asthma is associated with enhanced phosphorylation of JUN N-terminal kinase and failure of p38 mitogen-activated protein kinase/stress-activated protein kinase (JNK/SAPK) for survival. \textit{Journal of Allergy and Clinical Immunology} \textbf{105} 943–950.


Received 6 March 2003
Accepted 23 June 2003